Franklin Genomic Advancements ETF holds a quantitatively derived Neutral Morningstar Medalist Rating. The rating suggests the model does not express a clear expectation of outperformance or underperformance relative to peers over a full market cycle.
Franklin Genomic Advancements ETF HELX
Morningstar’s Analysis HELX
Will HELX outperform in the future?
Get our overall rating based on a fundamental assessment of the pillars below.
People Pillar
Parent Pillar
- Current Portfolio Date
- Equity Holdings —
- Bond Holdings —
- Other Holdings —
- % Assets in Top 10 Holdings 49.4
|
Top 10 Holdings
|
% Portfolio Weight
|
Market Value USD
|
Sector
|
|---|---|---|---|
Natera Inc | 10.16 | 4M | Healthcare |
Guardant Health Inc | 9.71 | 3M | Healthcare |
Krystal Biotech Inc | 4.91 | 2M | Healthcare |
Adaptive Biotechnologies Corp | 4.63 | 2M | Healthcare |
Ligand Pharmaceuticals Inc | 4.47 | 2M | Healthcare |
Twist Bioscience Corp | 4.36 | 2M | Healthcare |
BridgeBio Pharma Inc | 2.93 | 1M | Healthcare |
Medpace Holdings Inc | 2.87 | 1M | Healthcare |
United Therapeutics Corp | 2.72 | 966,021 | Healthcare |
Vertex Pharmaceuticals Inc | 2.59 | 919,618 | Healthcare |